Milestone Pharmaceuticals Announces Public Offering for $48.7M
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Milestone Pharmaceuticals ( (MIST) ) has issued an announcement.
On July 11, 2025, Milestone Pharmaceuticals announced an underwritten public offering of common shares and warrants, expected to raise approximately $48.7 million. The proceeds will support the clinical development and commercial launch of etripamil for PSVT, as well as general corporate purposes, potentially enhancing the company’s market positioning in cardiovascular treatments.
The most recent analyst rating on (MIST) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Milestone Pharmaceuticals stock, see the MIST Stock Forecast page.
Spark’s Take on MIST Stock
According to Spark, TipRanks’ AI Analyst, MIST is a Underperform.
Milestone Pharmaceuticals’ overall stock score reflects substantial financial difficulties, including no revenue and negative cash flows. However, the upcoming launch of CARDAMYST provides a potential turnaround opportunity, which is a significant positive factor. Technical indicators suggest a bearish trend, and valuation metrics highlight the lack of earnings and dividends, indicating a speculative investment.
To see Spark’s full report on MIST stock, click here.
More about Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company focused on developing and commercializing innovative cardiovascular medicines. The company recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for etripamil, intended for the treatment of paroxysmal supraventricular tachycardia (PSVT), an abnormal heart rhythm.
Average Trading Volume: 1,386,876
Technical Sentiment Signal: Sell
Current Market Cap: $83.4M
For an in-depth examination of MIST stock, go to TipRanks’ Overview page.
